On September 7, 2021 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported it will be participating in two upcoming virtual investor conferences (Press release, Lantern Pharma, SEP 7, 2021, View Source [SID1234587347]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Colliers Institutional Investor Conference
Panna Sharma, President & CEO of Lantern Pharma, will be hosting one-on-one meetings at the 2021 Colliers Institutional investor conference being held virtually September 9-10, 2021. Investors interested in arranging a meeting should contact their Collier sales representative.

H.C. Wainwright 23rd Annual Global Investment Conference
Mr. Sharma will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Lantern’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relations section of Lantern’s website at View Source Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.

On September 7, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, reported that it will participate in Citi’s 16th Annual BioPharma Virtual Conference 2021 investor conference (Press release, Novavax, SEP 7, 2021, View Source [SID1234587346]). Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Fireside Chat

Date:

Thursday, September 9, 2021

Time:

4:10 – 4:55 p.m. Eastern Time (ET)

Moderator:

Michael Guba

Novavax participants:

Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Conference

Event:

Investor meetings

Date:

Thursday, September 9, 2021

A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.

On September 7, 2021 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that the Company will present at three upcoming virtual investor conferences in September (Press release, Marker Therapeutics, SEP 7, 2021, View Source [SID1234587345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

H.C. Wainwright Annual Global Investment Conference
Company Presenter: Anthony H. Kim, Chief Financial Officer
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m. ET

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Company Presenter: Mythili Koneru, M.D., Ph.D., Chief Medical Officer
Date: Wednesday, September 22, 2021
Time: 9:05 a.m. ET

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Date: Monday, September 27, 2021
Time: 10:40 a.m. ET

Live webcasts of the presentations will be accessible from the Investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.

On September 7, 2021 Vaxart, Inc. (Nasdaq: VXRT) reported that Andrei Floroiu, President and CEO, and Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23rd Annual Global Investor Conference taking place Sept. 13-15, 2021 (Press release, Vaxart, SEP 7, 2021, https://www.prnewswire.com/news-releases/vaxart-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301370665.html [SID1234587344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on demand through the H.C. Wainwright conference portal by clicking here, beginning at 7:00 a.m. ET on Monday, Sept. 13, 2021, and on Vaxart’s website. The Company will also participate in one-on-one meetings during the conference.

Vaxart’s oral tablet COVID-19 vaccine is "The Pill that Moves the Needle" and the only oral COVID-19 vaccine whose potential is backed by clinical data. The Company’s oral tablet COVID-19 vaccine candidate has completed phase I trials and will enter phase II clinical trials this year.

On September 7, 2021 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) reported that Vanda’s management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021 (Press release, Vanda Pharmaceuticals, SEP 7, 2021, View Source [SID1234587343]). Vanda management will host investor meetings. Vanda has updated its corporate presentation, which may be accessed on Vanda’s website, www.vandapharma.com, by clicking on the Investors tab and following the Corporate Presentation link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!